Porokeratosis

Earn CME/CE in your profession:


Continuing Education Activity

Porokeratosis is an uncommon diagnosis that presents with keratotic papules or annular plaques with an elevated border. It usually occurs on sun-exposed skin, most commonly in the fifth decade of life, but can occur at any age and with similar frequencies in males and females. The increased occurrence of disseminated superficial actinic porokeratosis on sun-exposed skin likely indicates that ultraviolet light is a risk factor. While porokeratosis is usually an acquired disease, there is often a familial predisposition that could signify a hereditary component. This activity illustrates the evaluation, treatment, and complications of porokeratosis and the importance of a team approach to managing and surveillance of affected patients.

Objectives:

  • Describe the physical exam of a patient with porokeratosis.
  • Describe the evaluation of porokeratosis.
  • Review the management of porokeratosis.
  • Explain the importance of an interprofessional approach to managing and surveillance patients with porokeratosis.

Introduction

Porokeratosis is an uncommon dermatologic disorder. It is a disorder of keratinization that presents with keratotic papules or annular plaques with an elevated border.[1] It has a distinct histologic hallmark of cornoid lamella, which is a column of tightly fitted parakeratotic cells in the upper epidermis.[2][3] There are multiple clinical variants of porokeratosis, including disseminated superficial actinic porokeratosis, classical porokeratosis of Mibelli, porokeratosis palmaris plantaris et disseminatum, and linear porokeratosis.[2] 

Additionally, rare variants include genitogluteal porokeratosis, facial porokeratosis, giant porokeratosis, porokeratosis ptychotropica, hypertrophic verrucous porokeratosis, eruptive pruritic papular porokeratosis, follicular porokeratosis, and reticulate porokeratosis.[1] Variants can occur together but rarely do.[4][5][1] Porokeratosis is a precancerous lesion that can undergo malignant transformation.[6] Evaluation of porokeratosis is best with a biopsy of the elevated border. While multiple therapies exist for porokeratosis, including topical, systemic, and surgical, there are no standard guidelines for treatment.[7]

Etiology

Despite being first described over a century ago, the etiology and pathology of porokeratosis are unclear, complex, and multi-factorial.[3] Currently, suggested etiologies include ultraviolet light, trauma, genetics,  infectious agents, and immunosuppression.[8]

Epidemiology

Porokeratosis is an uncommon diagnosis. It usually occurs on sun-exposed skin, most commonly in the fifth decade of life, but can occur at any age and has similar frequencies in males and females.[2] The increased occurrence of disseminated superficial actinic porokeratosis on sun-exposed skin likely indicates that ultraviolet light is a risk factor.[9]

The eruptive form of porokeratosis correlates with immune suppression, transplantation patients, inflammatory states, and malignancy.[4]

Porokeratosis will progress to nonmelanoma skin cancer in 6.9% to 30% of cases, most frequently squamous cell carcinoma and less frequently basal cell carcinoma.[6]

While porokeratosis is usually an acquired disease, there is often a familial predisposition that could signify a hereditary component.[5]

Pathophysiology

Porokeratosis is an entity that results from the disordered progression of epidermal cells.[10] The development of this entity can be related to sun exposure. In areas where there has been no or limited sun exposure, repeated minor frictional trauma due to tight clothing may cause the entity, as is the case in genitourinary porokeratosis.[1] 

There is a reported association with overexpression of p53, and occasionally there can be an expansion of a clone of abnormal epidermal keratinocytes.[6][5] Porokeratosis has the possibility of malignant transformation into squamous cell carcinoma or basal cell carcinoma.[5]

Histopathology

The distinctive histopathologic feature of porokeratosis is a cornoid lamella, which is a column of tightly fitted parakeratotic cells.[2][3] The column of parakeratosis will occur over the epidermis with an absent granular layer and dyskeratotic cells in the upper spinous zone.[1] This feature is usually present at the elevated border of the lesion.[1] While once thought to be pathognomonic of porokeratosis, the feature has presented in other conditions.[10] Cornoid lamellation reflects a disordered progression of epidermal cells.[10] In follicular porokeratosis, the cornoid lamella can involve the follicular infundibulum.[11]

History and Physical

Porokeratosis presents as keratotic papules or annular plaques that expand centrifugally with an elevated keratotic border.[1] Centrally, the lesion can appear slightly atrophic.[1] The lesions can present with pruritus and may be present for several years before diagnosis.[1] Disseminated nodules present as pink to brown papules and macules with raised borders.[4] Porokeratosis most commonly occurs in the limbs and trunk but can occur in the trunk, face, genitourinary region, and scrotum.[11] However, porokeratosis as an entity has a broad spectrum of presentations, including large destructive lesions and the involvement of burn scars.[6]

Evaluation

Evaluation of porokeratosis is best with a biopsy of the elevated border.[1] Biopsy in this area will show the cornoid lamella and will be essentially diagnostic. Dermoscopy can also be useful for diagnosis. Dermoscopy of lesions shows central brown pigmentation with blue-gray dots surrounded by a single hypopigmented band with a white track at the periphery.[1]

Despite the relative rarity of porokeratosis, especially some subtypes like genitourinary porokeratosis, one should keep the diagnosis in mind due to the risk of malignant degeneration.[6]

Treatment / Management

Multiple therapies are described for porokeratosis, including topical, systemic, and surgical. However, there have been no randomized controlled trials, so there are no international guidelines on treatment standards.[7]

  • Classical porokeratosis of Mibelli is most successfully treated with imiquimod cream.[7]
  • Linear porokeratosis responds well to topical or systemic retinoids.[7]
  • Disseminated porokeratosis can be treated successfully with topical vitamin D acid derivatives.[7]
  • Surgical interventions or cryotherapy are options for treatment in areas where topical agents are challenging to use or contraindicated.[7] Laser therapy may be another treatment option.[4]
  • Topical steroids, retinoids, and topical diclofenac may provide symptomatic relief even if no lasting benefit occurs.[1]
  • In a small study, topical lovastatin was used to improve porokeratosis symptoms.[12]

Differential Diagnosis

Clinically porokeratosis can resemble psoriasis, lichen simplex chronicus, hypertrophic lichen planus, tuberculosis of the skin, Bowen disease, candidiasis, irritants, and allergic contact dermatitis.[1]

Prognosis

Porokeratosis is a premalignant condition[1]; however, all types of porokeratosis can undergo malignant transformation to non-melanoma skin cancer at a rate of 6.9 to 30%.[2][6] Most commonly, the lesion transforms into squamous cell carcinoma. Less frequently, the lesion transforms into basal cell carcinoma. If the lesion has not undergone a malignant transformation, excision is curative.

Linear porokeratosis and giant porokeratosis are the variants that are most susceptible to malignant transformation. Malignant transformation is rare in disseminated superficial actinic porokeratosis.[13]

Complications

Complications are based on treatment selection. General complications of surgical excision include infection, bleeding, and scarring. Topical treatments can irritate the skin or cause skin atrophy, pruritus, xerosis, or pigmentation changes. Complications can also be related to a lack of early diagnosis with a biopsy and a lack of treatment leading to the potential for malignant transformation. 

Deterrence and Patient Education

Patients should use sun protection, avoid excessive sunlight exposure, and go for periodic examinations by a dermatologist to monitor for recurrence or malignant transformation.[2]

Pearls and Other Issues

  • The hallmark of porokeratosis histologically is a cornoid lamella, which is a column of tightly fitted parakeratotic cells.[3]
  • Porokeratosis presents as keratotic papules or annular plaques that expand centrifugally with an elevated keratotic border.[1] Dermoscopy of lesions shows central brown pigmentation with blue-gray dots surrounded by a single hypopigmented band with a white track at the periphery.[1]
  • There are many variants of porokeratosis.[2]
  • Porokeratosis can undergo malignant transformation to squamous cell carcinoma and basal cell carcinoma.[6]
  • Evaluation of porokeratosis is best done with a biopsy of the elevated border.[1]
  • Multiple therapies are described for porokeratosis, including topical, systemic, and surgical. However, there have been no randomized controlled trials, so there are no international guidelines on treatment standards.[7]
  • Patients treated for porokeratosis should be advised to use sun protection, avoid excessive sunlight exposure, and go for periodic examinations by a dermatologist to monitor for recurrence or malignant transformation.[2]

Enhancing Healthcare Team Outcomes

Dermatologists and other clinicians should work closely with pathologists to ensure lesions receive an evaluation for the presence of malignant transformation.[2] [Level 5]

Dermatologists and dermatology specialty nurses should periodically follow up with patients to monitor for recurrence.[2] An interprofessional team approach to follow-up will provide the best patient outcomes. [Level 5]



(Click Image to Enlarge)
Disseminated Superficial Actinic Porokeratosis (DSAP)
Disseminated Superficial Actinic Porokeratosis (DSAP)
Contributed by DermNetNZ

(Click Image to Enlarge)
Porokeratosis
Porokeratosis
Contributed by DermNetNZ

(Click Image to Enlarge)
Porokeratosis of Mibelli
Porokeratosis of Mibelli
Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India
Article Details

Article Author

Grant M. Williams

Article Editor:

Eric P. Fillman

Updated:

9/28/2022 5:23:11 PM

References

[1]

Joshi R,Minni K, Genitogluteal porokeratosis: a clinical review. Clinical, cosmetic and investigational dermatology. 2018     [PubMed PMID: 29750048]

[2]

A report of 31 cases of porokeratosis at the National Skin Centre., Leow YH,Soon YH,Tham SN,, Annals of the Academy of Medicine, Singapore, 1996 Nov     [PubMed PMID: 9055013]

[2]

Sertznig P,von Felbert V,Megahed M, Porokeratosis: present concepts. Journal of the European Academy of Dermatology and Venereology : JEADV. 2012 Apr     [PubMed PMID: 21929548]

[4]

Le C,Bedocs PM, Disseminated Superficial Actinic Porokeratosis null. 2018 Jan     [PubMed PMID: 29083728]

[5]

Kanitakis J, Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features. European journal of dermatology : EJD. 2014 Sep-Oct     [PubMed PMID: 25115203]

[6]

Ahmed A,Hivnor C, A case of genital porokeratosis and review of literature. Indian journal of dermatology. 2015 Mar-Apr     [PubMed PMID: 25814761]

[7]

Weidner T,Illing T,Miguel D,Elsner P, Treatment of Porokeratosis: A Systematic Review. American journal of clinical dermatology. 2017 Aug     [PubMed PMID: 28283894]

[8]

Gu CY,Zhang CF,Chen LJ,Xiang LH,Zheng ZZ, Clinical analysis and etiology of porokeratosis. Experimental and therapeutic medicine. 2014 Sep;     [PubMed PMID: 25120591]

[9]

Neumann RA,Knobler RM,Jurecka W,Gebhart W, Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions. Journal of the American Academy of Dermatology. 1989 Dec     [PubMed PMID: 2584454]

[10]

Wade TR,Ackerman AB, Cornoid lamellation. A histologic reaction pattern. The American Journal of dermatopathology. 1980 Spring     [PubMed PMID: 7246969]

[11]

Zhao M,Sanusi T,Zhao Y,Huang C,Chen S, Porokeratosis with follicular involvement: report of three cases and review of literatures. International journal of clinical and experimental pathology. 2015     [PubMed PMID: 26097620]

[12]

Atzmony L,Lim YH,Hamilton C,Leventhal JS,Wagner A,Paller AS,Choate KA, Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal of the American Academy of Dermatology. 2020 Jan;     [PubMed PMID: 31449901]

[13]

Silver SG,Crawford RI, Fatal squamous cell carcinoma arising from transplant-associated porokeratosis. Journal of the American Academy of Dermatology. 2003 Nov     [PubMed PMID: 14576684]

[14]

Murase J,Gilliam AC, Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis. Journal of the American Academy of Dermatology. 2010 Nov;     [PubMed PMID: 20451293]

[15]

Lu JD,Mufti A,Sachdeva M,Rahat S,Lansang RP,Yeung J, Drugs associated with development of porokeratosis: A systematic review. Dermatologic therapy. 2021 Jan;     [PubMed PMID: 33210788]

[16]

Shin EJ,Gwak MJ,Jeong KH,Lee MH, Disseminated Superficial Actinic Porokeratosis in a Vitiligo Patient Undergoing Treatment with Long-Term Narrowband Ultraviolet B. Annals of dermatology. 2018 Apr;     [PubMed PMID: 29606833]

[17]

Herranz P,Pizarro A,De Lucas R,Robayna MG,Rubio FA,Sanz A,Contreras F,Casado M, High incidence of porokeratosis in renal transplant recipients. The British journal of dermatology. 1997 Feb;     [PubMed PMID: 9068727]

[18]

Kanitakis J,Euvrard S,Faure M,Claudy A, Porokeratosis and immunosuppression. European journal of dermatology : EJD. 1998 Oct-Nov;     [PubMed PMID: 9854155]

[19]

Bednarek R,Ezra N,Toubin Y,Linos K,Mousdicas N, Eruptive disseminated porokeratosis associated with corticosteroid-induced immunosuppression. Clinical and experimental dermatology. 2015 Oct;     [PubMed PMID: 25800103]

[20]

Niimi Y,Kawana S, Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl. European journal of dermatology : EJD. 2009 Jan-Feb;     [PubMed PMID: 19059828]

[21]

Sasson M,Krain AD, Porokeratosis and cutaneous malignancy. A review. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 1996 Apr;     [PubMed PMID: 8624658]

[22]

Das A,Vasudevan B,Talwar A, Porokeratosis: An enigma beginning to unravel. Indian journal of dermatology, venereology and leprology. 2022 May-Jun;     [PubMed PMID: 34877845]